AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $221.29
- 52-wk high
- $281.89
- High
- $221.29
- 52-wk low
- $179.75
- Low
- $215.97
- Prev close
- $219.58
- Mkt cap
- $31.49B
- P/E
- 21.1x
- Volume
- 861.1K
- Fwd P/E
- 18.3x
- Beta
- 0.77
- Div yield
- 1.09%
- P/S
- 5.6x
- P/B
- 4.8x
- Profit margin
- +27.0%
- Op margin
- +30.9%
- ROE
- +24.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 1.7% above what analysts expected.
Earnings per share
$2.90 expected
Reports Oct 29, 2026, in 46 days
EPS expected
$2.62 to $2.78
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.34B | $1.42B | $1.43B | $1.46B |
| Cost of what it sold | $514.8M | $538.1M | $540.4M | $602.4M |
| Gross profit | $820.8M | $884.7M | $891.0M | $861.2M |
| What it spent | ||||
| Research and development | $87.3M | $91.0M | $94.3M | $105.7M |
| Sales and admin | $259.2M | $278.4M | $285.7M | $296.3M |
| Other operating costs | $27.8M | $17.7M | $11.2M | $10.5M |
| Total operating expenses | $374.3M | $387.1M | $391.2M | $412.5M |
| What was left | ||||
| Operating profit | $446.5M | $497.6M | $499.8M | $448.7M |
| Interest on debt | $8.8M | $7.9M | $12.3M | $20.9M |
| Profit before tax | $446.8M | $496.1M | $502.3M | $474.2M |
| Tax | $98.3M | $103.6M | $103.6M | $90.7M |
| Net profit | $348.5M | $392.6M | $398.7M | $383.4M |
| EBITDA | $503.3M | $566.4M | $583.6M | $493.0M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
20 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
ResMed CEO Michael J. Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan
NeutralSep 10ResMed CEO Michael Farrell sells $1.11 million of company shares By Investing.com
NeutralSep 10ResMed CEO Michael Farrell sells $1.11 million of company shares By Investing.com
NeutralSep 10ResMed CEO Michael Farrell sells $1.11 million of company shares
NeutralSep 10Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating
NeutralSep 10Amundi Trims Holdings in ResMed Inc. $RMD
NeutralSep 10ResMed Inc. $RMD Shares Purchased by California State Teachers Retirement System
Leans bullishSep 9Farrell Peter C Disposes of 970 Shares in ResMed at $234.73 Each on September 2, 2026
Leans bearishSep 8
Macro
32 macro signals shaping RMD right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results